Swaroop Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 4.00 Cr
as on 24-10-2024
- Company Age 26 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 11.85 Cr
as on 24-10-2024
- Satisfied Charges ₹ 3.96 Cr
as on 24-10-2024
- Revenue -10.21%
(FY 2023)
- Profit -3.39%
(FY 2023)
- Ebitda 10.27%
(FY 2023)
- Net Worth 13.71%
(FY 2023)
- Total Assets -11.21%
(FY 2023)
About Swaroop Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 4.00 Cr.
The company currently has active open charges totaling ₹11.85 Cr. The company has closed loans amounting to ₹3.96 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Maheshwari, Vineet Kela, Puneet Kela, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24231UP1998PTC023440
- Company No.
023440
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 May 1998
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Aligarh, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Swaroop Pharmaceuticals?
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Maheshwari  | Director | 08-May-1998 | Current |
| Vineet Kela | Director | 08-May-1998 | Current |
| Puneet Kela | Director | 08-May-1998 | Current |
| Atul Agrawal | Director | 31-Mar-2008 | Current |
| Vijay Maheshwari | Director | 08-May-1998 | Current |
| Jaiprakash Agarwal | Director | 31-Mar-2008 | Current |
Financial Performance of Swaroop Pharmaceuticals.
Swaroop Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 10.21% decrease. The company also saw a slight decrease in profitability, with a 3.39% decrease in profit. The company's net worth Soared by an impressive increase of 13.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Swaroop Pharmaceuticals?
In 2023, Swaroop Pharmaceuticals had a promoter holding of 71.52% and a public holding of 28.48%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Subh Parenteral Private LimitedActive 3 years 11 months
Sanjay Maheshwari, Vineet Kela and 1 more are mutual person
- Man Safe Health Care Devices Private LimitedActive 16 years 4 months
Vineet Kela, Atul Agrawal and 1 more are mutual person
Charges (Loans)
₹11.85 Cr
₹3.96 Cr
Charges Breakdown by Lending Institutions
- Bank Of Baroda : 9.90 Cr
- Others : 1.95 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jul 2020 | Others | ₹6.50 M | Open |
| 30 Jul 2020 | Others | ₹1.30 Cr | Open |
| 16 Mar 2012 | Bank Of Baroda | ₹9.90 Cr | Open |
| 17 Sep 2008 | Bank Of India | ₹3.96 Cr | Satisfied |
How Many Employees Work at Swaroop Pharmaceuticals?
Swaroop Pharmaceuticals has a workforce of 18 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Swaroop Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Swaroop Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.